Robin Howard W's Form 4 filing
Nektar Therapeutics (NKTR) · filed Sep 11, 2025
- Accession no.
- 0000950170-25-114365
- Filed
- Sep 11, 2025
- Trade date
- Sep 9, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $311.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Robin Howard WCIK 0001206869 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2025 | Common Stock | SSaleDisposed | −2,100 | $45.16 | −$94,836 | 53,908 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,200 | $46.41 | −$55,692 | 52,708 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −2,156 | $47.49 | −$102,388.44 | 50,552 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,210 | $48.18 | −$58,297.8 | 49,342 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.